Lexicon Pharmaceuticals has made progress in getting its lead drug Inpefa onto formularies and securing reimbursement agreements with insurers. Multiple studies support the cost efficacy of Inpefa for ...
Lexicon Pharmaceuticals' launch of Inpefa continues to progress very slowly; prescriptions grew nearly 50% QoQ, but revenue is still below $2M and missing sell-side expectations. New leadership and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback